Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

This study has been completed.
Janssen, LP
Information provided by:
Armenteros, Jorge L., M.D., P.A.
ClinicalTrials.gov Identifier:
First received: February 28, 2006
Last updated: March 15, 2006
Last verified: March 2006

Primary objectives:

  1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD.
  2. To assess the short-term safety and tolerability of risperidone augmentation in the same group of subjects.

Condition Intervention Phase
Drug: Risperidone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Risperidone Augmentation for Treatment-Resistant Aggression in ADHD

Resource links provided by NLM:

Further study details as provided by Armenteros, Jorge L., M.D., P.A.:

Primary Outcome Measures:
  • Children' Aggression Scale

Secondary Outcome Measures:
  • Clinical Global Impressions

Estimated Enrollment: 25
Study Start Date: January 2003
Estimated Study Completion Date: April 2005
  Show Detailed Description


Ages Eligible for Study:   7 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Boys and girls ages 7 to 12 years, inclusive
  2. Medical/neurological clearance
  3. Meets DSM-IV diagnosis of ADHD
  4. Treatment with a stimulant medication during the last three weeks
  5. Failure to respond to stimulant medication as documented by:

    1. Three acts of aggression in the past week, two of which must be acts of physical aggression against other people, objects, or self
    2. Aggression Questionnaire (AQ) Predatory-Affective index score of 0 or below. This indicates primarily an affective or impulsive subtype of aggression
    3. Minimum CGI scale rating of 4 (moderately ill)
  6. IQ > 75 -

Exclusion Criteria:

  1. Major medical problems such as cardiac, renal, thyroid diseases, and seizure disorder
  2. History of alcohol or substance abuse within the last 4 weeks
  3. Previous adequate treatment with risperidone (2 mg/day for at least 4 weeks)
  4. Acutely suicidal or homicidal
  5. Unable to sign informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00297739

United States, Florida
Jorge L. Armenteros, M.D., P.A.
Coral Gables, Florida, United States, 33134
Sponsors and Collaborators
Armenteros, Jorge L., M.D., P.A.
Janssen, LP
Principal Investigator: Jorge L Armenteros, MD Jorge L. Armenteros, M.D., P.A.
  More Information

ClinicalTrials.gov Identifier: NCT00297739     History of Changes
Other Study ID Numbers: RIS-ATT-401 
Study First Received: February 28, 2006
Last Updated: March 15, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by Armenteros, Jorge L., M.D., P.A.:

Additional relevant MeSH terms:
Behavioral Symptoms
Antipsychotic Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Tranquilizing Agents

ClinicalTrials.gov processed this record on May 22, 2016